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Introduction 
Aldosterone is an important component of  the Renin-Angioten-
sin-Aldosterone System (RAAS) and plays an important role in 
controlling blood pressure in the body [36]. RAAS component 
genes can be candidates for evaluating predisposition to devel-
opment of  hypertension, cardiovascular disease, and progression 
of  renal disease in type 2 diabetes. The CYP11B2 gene encodes 
a steroid 11/18-beta-hydroxylase that functions in mitochondria 
in the zona glomerulosa of  the adrenal cortex to synthesize the 
mineralocorticoid aldosterone, and its expression is regulated by 
angiotensin II and potassium [6]. The CYP11B2 gene contains 9 
exons and 8 introns and is located on chromosome 8q22 [4, 11, 
15, 18].
The -344 C/ T variant is a commonly reported polymorphism of  
the CYP11B2 gene, which is located in the promoter region of  
the gene [2]. The CYP11B2 gene polymorphism is associated with 
serum aldosterone level and production [13, 24, 35], blood pres-
sure [4, 30, 7, 14], left ventricular size and mass [15, 34], ischemic 
stroke [25], and essential hypertension. This association with risk 
of  hypertension was found to be confined to male subjects in the 
south Indian Tamil population [22, 23].
CYP11B2 gene association studies have been conducted exten-
sively in subjects who suffer from hypertension and come from 
Caucasian, Asian, and Indian populations [1, 4, 7, 10, 19, 22, 26, 
29, 31, 32, 33] but only a few studies have been conducted in an 
Indian population  with subjects suffering from type 2 diabetes 
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(T2DM)  [20, 21]. 
Therefore the aim of  the present study is to investigate the asso-
ciation between the CYP11B2 (-344 C/T) polymorphism and sex 
in type 2 diabetic patients in an Indian population.
Materials & Methods
Ethics
Ethical committee clearance was obtained from the respective 
medical institutions prior to the recruitment of  subjects for this 
study. Informed consent was obtained from all the participants 
prior to their recruitment for the study.
Subjects
This is a sex-based case control study, consisting of  183 males 
(T2DM =110, Con = 73) and 141 females (T2DM =96, CON 
= 45). Registered T2DM subjects were recruited at two partici-
pating medical institutions, namely (a) Calcutta Medical College 
(Kolkata), (b) B.P. Poddar Hospital &Research Centre (Kolkata).
Healthy unrelated controls were randomly selected and recruited 
from local community centers.
Biochemical Analysis 
Venous blood (10 ml) was collected from each individual included 
in the study for biochemical (5 ml) and genetic analysis (5 ml). 
Biochemical analyses to determine glucose (mg/dl), cholesterol 
(mg/dl), triglyceride (mg/dl), HDL cholesterol (mg/dl), and LDL 
cholesterol was performed by using automated analyzer (EM 360, 
TRANSASIA).
CYP11B2 gene analysis
Approximately 5ml of  venous blood was drawn from each of  the 
subjects in EDTA vials and genomic DNA was extracted from 
whole fresh blood using standard salting out method using phe-
nol-chloroform [17]. The CYP11B2 (-344 C/T) polymorphism 
was identified by PCR-RFLP and sequencing. Subjects were gen-
otyped using primers CAGGAGGAGACCCCATGTGA (sense) 
and CCTCCACCCTGTTCAGCCC (antisense). PCR amplifica-
tion was performed in a final volume of  10μL reaction mixture 
containing 50ng of  genomic DNA, 20 pmol of  each primer, 10X 
Taq PCR buffer, 25 mM MgCl2, 100 mM of  each dNTPs and 0.5 
U/uL of  Red Taq polymerase. PCR amplification was performed 
in a DNA thermo cycler (Bio-Rad). PCR was carried out with an 
initial denaturing time at 95°C for 5 min. Then the DNA was am-
plified for 35 cycles with denaturation at 94°C for 1 min, anneal-
ing at 69°C for 1:30 min and extension at 72°C for 1:30 min and 
final extension 72°C for 10 min. The PCR products were checked 
by 1% agarose gel electrophoresis with ethidium bromide staining 
and directly visualized in UV light.
Restriction fragment length polymorphism (RFLP) analysis was 
performed by restriction endonuclease Hae III and by incubating 
at 37°C for 3 h and 30 min. Electrophoresis of  the digested sam-
ples was done in 2.5% agarose gel with ethidium bromide staining 
and analyzed under UV light. The C alleles were detected as frag-
ments of  202 bp and the T alleles as fragments of  273 bp plus 
smaller fragments (138bp, 125bp, and 71 bp) in each case. The 
genotypes were confirmed by direct sequencing (DNA Analyzer 
3730 ABI, Applied Bio system, USA) (Figure 1).
Statistical Analysis
Data were analyzed using SPSS Version 16.0 (SPSS Inc., Chicago, 
IL, USA). Data were expressed as Mean±SD. Student’s t-test and 
ANOVA test were used to determine differences in means and 
significance levels. Genotype and allele frequencies of  the CY-
P11B2 gene polymorphism were compared between males and 
females in type 2 diabetic patients (T2DM) and controls using 
Figure 1. Sequence chromatogram for rs1799998 (-344 C/T). Y represents the presence of  C and T, Heterozygous CT (Line 
1 and 4), line 2 represents Homozygous - CC and line 3 represents Homozygous - TT. Color coding of  the peaks: green, 
adenine (A); blue, cytosine (C); black, guanine (G); red, thymine (T).
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χ2-test. To compare the genotype and allelic distributions between 
two study groups, the Pearson χ2-test, Odds Ratio (OR), and Risk 
Ratio (RR) with 95% confidence interval (CI) were also calculated 
using an online calculator (http://www.vassarstats.net/odds2x2.
html?).Statistical significance was assumed at the P < 0.05 level.
Results and Discussion
Clinical characteristics of  all subjects
Baseline clinical characteristics of  males and females with type 2 
diabetes and healthy controls are presented in Table1. The DBP 
and HDL values were significant between total male and female 
subjects (p <0.05), whereas only DBP was significant between 
T2DM male and T2DM female subjects and HDL was significant 
between male and female controls (p <0.05). In contrast, no sig-
nificant difference was observed for age, BMI, SBP, glucose, cho-
lesterol, triglycerides and LDL between males and females with 
T2DM and controls.
Genotypic and allelic distribution of  the CYP11B2 gene pol-
ymorphism 
Sex-wise distribution of  theCYP11B2 gene genotype along with 
allele frequencies among subjects with Type 2 diabetes and healthy 
controls are presented in Table 2. The frequencies of  CYP11B2 
gene CC, CT, and TT genotypes were 14.55%, 50.00%, and 
35.45% for males with T2DM and 20.55%, 34.25%, and 45.21% 
for  male controls . Genotype distributions of  the CYP11B2 poly-
morphism differ between T2DM male subjects and male controls 
but are not statistically significant (χ2 = 4.485, p< 0.106). The CC, 
CT, and TT genotypes account for 11.46%, 54.17%, and 34.38% 
of  the T2DM female subjects, and 11.11%, 44.44%, and 44.44% 
of  the female  controls( χ2 = 1.397, p<0.497).This table shows 
that the CT heterozygote occurs more often in the T2DM sub-
jects than in the controls.
The C allele was a little more frequent among the T2DM male 
subjects (39.55%) than among the male controls (37.67%) but the 
T allele was more frequent among the male controls (62.33%) 
than among the T2DM male subjects (60.45%). The table shows 
that the C allele was also a bit more frequent among the T2DM fe-
male subjects (38.54%) than among the female controls (33.33%). 
Conversely, the T allele was more frequent among the female con-
trols (66.67%) than among the T2DM female subjects (61.46%). 
Overall, neither the frequencies of  the CYP11B2 genotypes nor 
their allele frequencies differed significantly among the different 
study groups.
The difference in CYP11B2 genotypes and allele frequencies be-
tween any two different study groups along with χ2, p value, odds 
ratio, and risk ratio are presented in Table 3. If  we look at geno-
typic combinations and the allele frequencies, we see no signifi-
cant associations between any of  the two studied groups.
In this cross-sectional study, we could not observe any signifi-
cant differences in genotype and allele frequency of  the CYP11B2 
(-344 C/T) polymorphism between males and females in T2DM 
subjects and controls (p<0.05). Several studies have found an as-
sociation between this polymorphism and hypertension [5, 27, 
30] left ventricle size and mass [15, 28], and myocardial infarction 
[34, 9]. Studies on the CYP11B2 (-344 C/T) polymorphism have 
shown positive [4, 7, 33, 16, 31] and negative associations [26, 32, 
10, 37] with hypertension and other cardiovascular parameters. 
[8] reported a significant association between the CYP11B2 gene 
polymorphism and renal insufficiency in hypertensive subjects, 
and an association with hypertension has been reported in south 
Indian male subjects [22, 23]. A recent study from Europe in a 
French population has reported that the CYP11B2 (-344 C/T) 
polymorphism is associated with T2DM and hypertension and 
that metabolic syndrome varies by gender [3], whereas Purkait et 
al., (2013) have reported no association between the CYP11B2 
gene polymorphism, T2DNH, and T2DM subjects in an Indian 
population, probably due to the small sample size.
Conclusion
We did not find any statistically significant association of  CY-
P11B2 (-344 C/T) polymorphism with Sex (males and females) 
in Indian T2DM subjects. It is also possible that type 2 diabetic 
patients with a high risk CYP11B2 genotype may be underrepre-
sented in the present study because of  premature cardiovascular-
Table 1. Basic clinical characteristics of  males and females with T2DM and male and female controls.
Parameters Total Study Group (N=324) T2DM (N= 206) CONTROL (N=118)
Male (N=182) Female (N=142 ) Male (N=109) Female (N= 97) Male (N= 73) Female (N= 45)
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Age (Year) 51.87 ± 10.62 52.63 ± 8.77 54.76 ± 11.50 54.26 ± 8.99 47.56 ± 7.33 49.13 ± 7.19
BMI (kg/m2) 24.55 ± 3.80 24.86 ± 4.58 24.84 ± 4.15 24.75 ± 4.77 24.29 ± 3.47 24.99 ± 4.36
SBP(mmHg) 136.66 ± 23.46 135.01 ± 25.98 143.57 ± 24.36 142.40 ± 23.02 126.34 ± 17.69 119.07 ± 25.04
DBP(mmHg) 86.23 ± 11.36 83.51 ± 11.54* 88.02 ± 12.07 84.31 ± 11.23* 83.56 ± 9.70 81.80 ± 12.14
Glucose
(mg/dl)
141.29 ± 66.91 139.64 ± 46.09 169.75 ± 85.91 160.38 ± 51.66 116.34 ± 25.47 112.91 ± 13.00
Cholesterol
(mg/dl)
164.99 ± 45.21 172.88 ± 40.31 168.44 ± 50.96 179.09 ± 39.92 159.85 ± 34.61 159.49 ± 38.23
Triglycerides
(mg/dl)
166.53 ± 87.47 161.84 ± 68.52 169.95 ± 93.72 174.23 ± 66.53 161.41 ± 77.54 135.11 ± 65.72
HDL (mg/dl) 45.06 ± 16.02 50.14 ± 17.36* 49.87 ± 17.59 51.49 ± 16.08 37.88 ± 9.68 47.24 ± 19.74*
LDL (mg/dl) 95.16 ± 29.70 97.66 ± 26.17 94.21 ± 33.78 98.74 ± 26.52 96.58 ± 22.42 95.32 ± 25.53
Variables are expressed as the mean± SD values; *P<0.05 between males and females
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Table 2. Sex-based distribution of  genotype and allele frequencies of  the CYP11B2 (-344 C/T) polymorphism in T2DM 
subjects and controls.
GENOTYPE MALE FEMALE
T2DM CON T2DM CON
N (%) N (%) N (%) N (%)
CC 16 (14.55) 15 (20.55) 11 (11.46) 5 (11.11)
CT 55 (50.00) 25 (34.25) 52 (54.17) 20 (44.44)
TT 39 (35.45) 33 (45.21) 33 (34.38) 20 (44.44)
χ 2  = 4.485 , p = 0.106 χ 2  = 1.397 , p = 0.497
ALLELE
C 87 (39.55) 55 (37.67) 74 (38.54) 30 (33.33)
T 133 (60.45) 91 (62.33) 118 (61.46) 60 (66.67)
Table 3. Statistics of  genotype and allele distribution of  the CYP11B2 gene polymorphism in T2DM subjects and controls.
Study Group Statistics C Vs T CC Vs TT CT Vs  TT
CC Vs 
CT
(CC+CT) 
Vs TT
CC Vs 
(CT+TT)
T2DM
Vs
CON
χ 2 0.59 0.00 4.91 2.74 3.14 0.89
P 0.439 1.000 0.267 0.098 0.076 0.345
OR
(95%CI)
0.8776 (0.6301 - 
1.2224)
1.0063
(0.5106 - 
1.9831)
0.571
(0.3475 - 
0.9392)
1.7613
(0.8968 
-3.4593)
0.659
(0.4151 
-1.0461)
1.353
(0.7217 - 
2.5366)
RR
(95% CI)
0.9522
(0.8419 - 1.0769)
1.0017
(0.8321 - 
1.2059)
0.7438
(0.5762 - 
0.9601)
1.1534
(0.9605 
-1.3851)
0.7782
(0.5921 
-1.0226)
1.0463
(0.9493 - 
1.1531)
MALE
T2DM
Vs
CON
 χ 2 0.13 0.06 3.42 2.85 1.75 1.12
P 0.718 0.806 0.064 0.091 0.186 0.29
OR
(95% CI)
0.924
(0.6009 - 1.4207)
1.108
(0.4767 - 
2.5749)
0.5372
(0.2771 - 
1.0416)
2.0625
(0.883 - 
4.8176)
0.6658
(0.3639 
-1.2183)
1.5194
(0.6988 
-3.3037)
RR
(95% CI)
0.9699
(0.8221 - 1.1443)
1.0314
(0.7992 - 
1.331)
0.7292
(0.5251 
-1.0126)
1.2394
(0.9453 
-1.625)
0.7843
(0.5489 
-1.1207)
1.0755
(0.9352 
-1.237)
FEMALE
T2DM
Vs
CON
χ 2 0.71 0.22 1.39 0.03 1.32 0.00
P 0.399 0.639 0.238 0.499 0.251 1.000
OR
(95% CI)
0.7973
(0.4712 -1.349)
0.75
(0.2272 - 
2.4756)
0.6346
(0.2974 
-1.3542)
1.1818
(0.3645 - 
3.8316)
0.6548
(0.3177 - 
1.3496)
0.9659
(0.3145 
-2.9662)
RR
(95% CI)
0.9219
(0.7669 - 1.1082)
0.9375
(0.723 - 
1.2157)
0.7765
(0.5158 
-1.1688)
1.0317
(0.8226 - 
1.2941)
0.7734
(0.5042 - 
1.1865)
0.9961
(0.8783 
-1.1297)
T2DM
Male
Vs
Female
χ 2 0.04 0.21 0.13 0.53 0.03 0.43
P 0.841 0.647 0.718 0.467 0.862 0.512
OR
(95% CI)
0.9587
(0.6446 -1.4257)
0.8125
(0.3314 
-1.992)
1.1174
(0.6139 
-2.0336)
0.7272
(0.3089 
-1.7119)
1.0487
(0.5904 
-1.8626)
0.7603
(0.3342 
-1.7294)
RR
(95% CI)
0.9837
(0.8426 - 1.1484)
0.9455 
(0.7435 
-1.2023)
1.0687
(0.7464 
-1.5302)
0.9385
(0.7924 
-1.1116)
1.0314
(0.7095 
-1.4994)
0.9651
(0.8685 
-1.0725)
CONTROL
Male
Vs
Female
χ 2 0.45 1.05 0.45 2.21 0.01 1.76
P 0.502 0.306 0.502 0.137 0.920 0.185
OR
(95% CI)
0.8273
(0.4766-1.36) 0.55 (0.1734 -1.7449)
1.32
(0.5879-
2.9638)
0.4167
(0.1292-
1.3432)
1.0312
(0.4885-
2.1769)
0.4833
(0.1626-
1.4366)
RR
(95% CI)
0.9349
(0.7708-1.134)
0.8594
(0.6537-
1.1297)
1.1379
(0.7763-
1.668)
0.7813
(0.5731-
1.0651)
1.0171
(0.673-
1.5371)
0.8938
(0.7649-
1.4366)
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related mortality.
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